Day 1 | Day 2 | Download Brochure | Short Course
Wednesday, August 17
7:30 am Morning Coffee (Breakfast Sponsored Presentation – Opportunity Available)
8:25 Chairperson's Remarks
J. Tyler Martin, M.D., President and CMO, Dynavax Technologies
8:30 TB Vaccine Development Progress Report
Lewellys F. Barker, M.D., M.P.H., Senior Medical Advisor, Aeras Global TB Vaccine Foundation - Biography
Progress in TB vaccine research and development over the past decade is continuing through partnerships between the public, private (pharmaceutical and biotech industries), and academic sectors via nonprofit organizations like the Aeras Global TB Vaccine Foundation and the TB Vaccine Initiative (TBVI). The main focus is on developing a heterologous prime-boost vaccine regimen that could include a replacement for current BCGs such as a recombinant BCG as the prime, and boosting with one of several novel vaccine candidates, including viral vectored and fusion protein vaccines. The talk will describe and provide a progress report on the TB vaccines candidates in clinical development as well as promising candidates and concepts in the pre-clinical pipeline.
9:00 Results of an Investigational Vaccine for Hepatitis B in Adults
J. Tyler Martin, M.D., President and CMO, Dynavax Technologies- Biography
Novel vaccines can provide significant medical benefits to populations where traditional vaccines are less effective. Adults with Chronic Kidney Disease are at high risk for hepatitis B infection and current vaccines respond poorly in this immunocompromised population. Immunogenicity of an investigational vaccine using a novel TLR9 agonist adjuvant has been compared in a large Phase 3 trial with the widely used vaccine Engerix-B. Results will demonstrate the promise of applying novel adjuvants to existing vaccine for patient benefit.
9:30 Adenoviral Vector-Based Hepatitis C Virus Vaccine
Jan Pravsgaard Christensen, Ph.D., Associate Professor, Faculty of Health Sciences, Institute of International Health, Immunology and Microbiology, University of Copenhagen - Biography
Potent and broad cellular immune responses against the non-structural proteins of hepatitis C virus (HCV) are associated with spontaneous viral clearance. We have improved the immunogenicity of an adenovirus (Ad) based HCV vaccine by fusing NS3 from HCV (Strain J4; Genotype 1b) to the MHC class II chaperone protein invariant chain (Ii). From previous work using LCMV infection as a model, we know that fusion of Ii to gene of interest will induce an accelerated, increased response towards the gene, broaden the response towards several epitopes in the gene, and induce stabilized life-long response. In this talk, efficiency of this approach will be demonstrated.
10:00 Networking Coffee Break with Exhibit and Poster Viewing
10:45 Vaccines to Elicit Broadly Neutralizing Antibodies Against the Membrane Proximal External Region of HIV gp41
Jamie Kathleen Scott, M.D., Ph.D., Professor & Canada Research Chair in Molecular Immunity, Molecular Biology & Biochemistry, Simon Fraser University - Biography
The membrane proximal external region of HIV gp41 (MPER) bears epitopes for 2 broadly neutralizing antibodies and 2 cross-neutralizing antibodies against HIV; as such, it represents a prime target for neutralizing antibodies produced by a vaccine. However multiple attempts at mimicking the "neutralization competent structure" (NCS) of the MPER have failed in being immunogenic, but unable to elicit neutralizing antibodies. We have developed a DNA vaccine candidate that expresses the MPER in the context of the cell membrane and tethered to the gp41 transmembrane region. The MPER presented in this way appears reproduce the NCS of the MPER, as neutralizing antibodies, but not their non-neutralizing mutant counterparts, bind to it. Results of immunizations with this DNA vaccine and future plans for a DNA-prime, liposome-boost vaccine strategy will be presented.
11:15 Pre-Clinical Development of ACAM529, A Replication-Defective Vaccine Against Herpes Simplex Virus Type 2
Simon Delagrave, Ph.D., Director, Biotherapeutics, Discovery North America, sanofi pasteur - Biography
ACAM529 is a replication-defective HSV-2 vaccine better known in the scientific literature as dl5-29, which is currently being prepared for clinical trials. The vaccine has been cloned, grown in a complementing cell line, purified according to a scalable process, and administered to mice via various routes to assess immunogenicity as well as protective efficacy in a vaginal challenge model. ELISA and neutralization titers, as well as measurements of morbidity, mortality, and vaginal shedding of the challenge virus indicate that two doses of ACAM529 delivered intramuscularly are optimal to protect animals against a lethal challenge.
11:45 Novel Vaccine Design Based on the Identification of Protective T Cell Antigens through Directed Delivery of the
C. trachomatis ORFeome to Antigen Presentation Pathways in Human PBMC
Jessica Flechtner, Ph.D., Vice President, Research, Genocea Biosciences, Inc.
Genocea Biosciences has applied its proprietary T cell antigen identification platform to the human pathogen Chlamydia trachomatis with the goal of selecting protein antigens associated with control of infection. We identified statistically significant differences in proteins eliciting T cell responses from subjects who controlled infection compared to those who did not. The identification of antigens associated with clinical control of infection, in addition to discrimination of antigens associated with T cell responses in patients with severe disease, is an important step toward the development of a safe and effective C. trachomatis vaccine.
12:15pm End of Novel Vaccines: Design & Development
Day 1 | Day 2 | Download Brochure | Short Course